Premarket Decliner
ACET Adicet Bio9.02+0.75+9.1%
Premarket:7.96-1.06 (-11.8%)
Adicet Bio Announces Positive Safety and Efficacy Data from Prula-cel (formerly ADI-001) Study in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
Business WireMon, 28-Sep 6:45 AM
After Hours Gainer
After Hours:9.90+0.88 (+9.8%)
Adicet Bio to Host Webcast to Present Prula-cel (formerly ADI-001) Clinical Data in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis
Business WireFri, 25-Sep 4:00 PM
ACET Adicet Bio8.98+0.71+8.6%
After Hours:10.10+1.12 (+12.5%)
ACET Adicet Bio9.01+0.06+0.7%
After Hours:9.27+0.26 (+2.9%)
Adicet Bio Announces FDA Clearance of IND Application for ADI-212
Business WireThu, 27-Aug 4:00 PM
ACET Adicet Bio4.66-0.07-1.5%
After Hours:5.22+0.56 (+12.0%)
Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)
Business WireMon, 26-Jun 4:00 PM
ACET Adicet Bio20.82+0.08 (+0.4%)
